A detailed history of Versant Capital Management, Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 69 shares of NUVL stock, worth $6,658. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69
Previous 69 -0.0%
Holding current value
$6,658
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 27, 2025

BUY
$72.16 - $86.48 $4,979 - $5,967
69 New
69 $5,000
Q1 2025

Apr 03, 2025

BUY
$67.38 - $88.96 $2,560 - $3,380
38 New
38 $2,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.15B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.